Skip to main content

Table 4 HR estimates of overall survival* by TP53 R72P, MDM2 SNP309 and p53

From: Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients

TP53R72P**

HR

Lower and upper limit 95% CI

Pvalue

ABCS

    

   GC

0.99

0.79

1.26

0.95

   CC

0.72

0.45

1.16

0.17

HABCS

    

   GC

1.40

0.60

3.45

0.46

   CC

2.54

0.69

9.34

0.16

HEBCS

    

   GC

1.17

0.82

1.67

0.40

   CC

1.72

1.00

2.98

0.05

SEARCH

    

   GC

1.18

0.95

1.49

0.14

   CC

0.93

0.59

1.48

0.77

Pooled

    

   GC

1.11

0.96

1.28

0.18

   CC

1.00

0.76

1.31

0.97

MDM2 SNP309**

    

ABCS

    

   TG

0.93

0.73

1.18

0.54

   GG

0.99

0.70

1.40

0.97

HABCS

    

   TG

0.60

0.25

1.46

0.26

   GG

0.36

0.08

1.65

0.19

HEBCS

    

   TG

0.76

0.53

1.11

0.16

   GG

0.91

0.56

1.47

0.69

SEARCH

    

   TG

1.03

0.82

1.31

0.78

   GG

1.43

1.03

1.97

0.03

Pooled

    

   TG

0.93

0.80

1.08

0.34

   GG

1.11

0.90

1.37

0.31

p53 status tumor **

    

ABCS

    

   p53 positive

1.31

0.96

1.80

0.09

HEBCS

    

   p53 positive

1.93

1.27

2.94

0.002

Pooled

    

   p53 positive

1.50

1.16

1.93

0.002

Breast cancer-specific survival

Pooled

    

   p53 positive

1.57

1.20

2.05

0.001

  1. *Overall survival including all studies unless otherwise specified; ** HRs of heterozygous and homozygous rare allele groups have been calculated by comparison to the reference categories of common alleles: TP53 R72P = GG; MDM2 SNP309 = TT; p53 = negative tumors; Pooled analyses have been adjusted for study.